Radioactive Stents Market

Executive Summary

Radioactive Stents Market was valued at US $409.08 million in 2021 and is projected to grow at 3.83% CAGR over the forecast period to reach US $512.52 million by 2027. Radioactive Stents Market represented US $29.61 million opportunity over 2019-2021 and estimated to create US $103.44 million opportunity in 2027 over 2021.

Radioactive Stents from Consainsights analyses the Radioactive Stents Market in the Life Sciences industry over the forecast period to 2027.

Radioactive Stents research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.

Radioactive Stents segmentation includes Product, Application, Stent Size, Region and Geography.

Based on the Product, the Radioactive Stents analysis covers RETROGRADE STENTS, ANTEGRADE STENTS, INTERNAL (DOUBLE-J) STENTS, IODINE-125 RADIOACTIVE STENTS, OTHERS.

In Product segment, RETROGRADE STENTS segment has highest cagr growth of 3.40%.

Based on the Application, the Radioactive Stents analysis covers LITHOTRIPSY, URETEROSCOPY, URETEROENOSCOPY, PERCUTANEOUS NEPHROLITHOTOMY, ANGIOGRAPHY, NEOINTIMAL HYPERPLASIA, ESOPHAGEAL CANCER, BILIARY CANCER, OTHERS.

In Application segment, LITHOTRIPSY segment has highest cagr growth of 3.40%.

Based on the Stent Size, the Radioactive Stents analysis covers 18 MM, 20 MM, 14 MM, OTHERS.

In Stent Size segment, 18 MM segment has highest cagr growth of 3.40%.

Based on the Region, the Radioactive Stents analysis covers NORTH AMERICA, EUROPE, ASIA-PACIFIC, LAMEA.

In Region segment, NORTH AMERICA segment has highest cagr growth of 3.40%.

Based on the region, the Radioactive Stents analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.

Key companies operating in the market include C.R. BARD, INC., COOK MEDICAL INC., MEDLINE INDUSTRIES LTD, PNN MEDICAL A/S, ALLIUM MEDICAL SOLUTIONS LTD., APC CARDIOVASCULAR LTD., MICRO-TECH PVT. LTD., CHANGZHOU ZHIYE CO LTD., AETNA INC., ABBOTT LABORATORIES and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.

Market Overview

Definition & Scope

The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.

The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.

The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.

Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.

Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.

As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.

Currency, Year & Forecast

The currency used in this report is USD, with the market size indicated in terms of USD million/billion.

For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.

For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.

Product

Introduction

In 2021, RETROGRADE STENTS segment has the highest revenue of US $195.77 million and is expected to grow at CAGR of 3.40% by 2027 RETROGRADE STENTS segment has highest cagr growth of 3.40%.

RETROGRADE STENTS

RETROGRADE STENTS segment was valued at US $181.60 million in 2019 and is projected to grow at 3.40% CAGR over the forecast period to reach US $245.27 million by 2027. RETROGRADE STENTS segment represented US $14.17 million opportunity over 2019-2021 and estimated to create US $49.50 million opportunity in 2027 over 2021.

ANTEGRADE STENTS

ANTEGRADE STENTS segment was valued at US $96.24 million in 2019 and is projected to grow at 3.40% CAGR over the forecast period to reach US $129.98 million by 2027. ANTEGRADE STENTS segment represented US $7.51 million opportunity over 2019-2021 and estimated to create US $26.23 million opportunity in 2027 over 2021.

INTERNAL (DOUBLE-J) STENTS

INTERNAL (DOUBLE-J) STENTS segment was valued at US $57.00 million in 2019 and is projected to grow at 3.40% CAGR over the forecast period to reach US $76.99 million by 2027. INTERNAL (DOUBLE-J) STENTS segment represented US $4.45 million opportunity over 2019-2021 and estimated to create US $15.54 million opportunity in 2027 over 2021.

IODINE-125 RADIOACTIVE STENTS

IODINE-125 RADIOACTIVE STENTS segment was valued at US $31.02 million in 2019 and is projected to grow at 3.40% CAGR over the forecast period to reach US $41.90 million by 2027. IODINE-125 RADIOACTIVE STENTS segment represented US $2.42 million opportunity over 2019-2021 and estimated to create US $8.46 million opportunity in 2027 over 2021.

OTHERS

OTHERS segment was valued at US $13.61 million in 2019 and is projected to grow at 3.40% CAGR over the forecast period to reach US $18.39 million by 2027. OTHERS segment represented US $1.06 million opportunity over 2019-2021 and estimated to create US $3.71 million opportunity in 2027 over 2021.

Application

Introduction

In 2021, LITHOTRIPSY segment has the highest revenue of US $158.44 million and is expected to grow at CAGR of 3.40% by 2027 LITHOTRIPSY segment has highest cagr growth of 3.40%.

LITHOTRIPSY

LITHOTRIPSY segment was valued at US $146.98 million in 2019 and is projected to grow at 3.40% CAGR over the forecast period to reach US $198.51 million by 2027. LITHOTRIPSY segment represented US $11.47 million opportunity over 2019-2021 and estimated to create US $40.06 million opportunity in 2027 over 2021.

URETEROSCOPY

URETEROSCOPY segment was valued at US $92.36 million in 2019 and is projected to grow at 3.40% CAGR over the forecast period to reach US $124.74 million by 2027. URETEROSCOPY segment represented US $7.21 million opportunity over 2019-2021 and estimated to create US $25.18 million opportunity in 2027 over 2021.

URETEROENOSCOPY

URETEROENOSCOPY segment was valued at US $54.10 million in 2019 and is projected to grow at 3.40% CAGR over the forecast period to reach US $73.07 million by 2027. URETEROENOSCOPY segment represented US $4.22 million opportunity over 2019-2021 and estimated to create US $14.75 million opportunity in 2027 over 2021.

PERCUTANEOUS NEPHROLITHOTOMY

PERCUTANEOUS NEPHROLITHOTOMY segment was valued at US $33.53 million in 2019 and is projected to grow at 3.40% CAGR over the forecast period to reach US $45.29 million by 2027. PERCUTANEOUS NEPHROLITHOTOMY segment represented US $2.62 million opportunity over 2019-2021 and estimated to create US $9.14 million opportunity in 2027 over 2021.

ANGIOGRAPHY

ANGIOGRAPHY segment was valued at US $20.59 million in 2019 and is projected to grow at 3.40% CAGR over the forecast period to reach US $27.81 million by 2027. ANGIOGRAPHY segment represented US $1.61 million opportunity over 2019-2021 and estimated to create US $5.61 million opportunity in 2027 over 2021.

NEOINTIMAL HYPERPLASIA

NEOINTIMAL HYPERPLASIA segment was valued at US $15.18 million in 2019 and is projected to grow at 3.40% CAGR over the forecast period to reach US $20.51 million by 2027. NEOINTIMAL HYPERPLASIA segment represented US $1.18 million opportunity over 2019-2021 and estimated to create US $4.14 million opportunity in 2027 over 2021.

ESOPHAGEAL CANCER

ESOPHAGEAL CANCER segment was valued at US $6.94 million in 2019 and is projected to grow at 3.40% CAGR over the forecast period to reach US $9.37 million by 2027. ESOPHAGEAL CANCER segment represented US $0.54 million opportunity over 2019-2021 and estimated to create US $1.89 million opportunity in 2027 over 2021.

BILIARY CANCER

BILIARY CANCER segment was valued at US $6.36 million in 2019 and is projected to grow at 3.40% CAGR over the forecast period to reach US $8.59 million by 2027. BILIARY CANCER segment represented US $0.50 million opportunity over 2019-2021 and estimated to create US $1.73 million opportunity in 2027 over 2021.

OTHERS

OTHERS segment was valued at US $3.44 million in 2019 and is projected to grow at 3.40% CAGR over the forecast period to reach US $4.64 million by 2027. OTHERS segment represented US $0.27 million opportunity over 2019-2021 and estimated to create US $0.94 million opportunity in 2027 over 2021.

Stent Size

Introduction

In 2021, 18 MM segment has the highest revenue of US $201.01 million and is expected to grow at CAGR of 3.40% by 2027 18 MM segment has highest cagr growth of 3.40%.

18 MM

18 MM segment was valued at US $186.46 million in 2019 and is projected to grow at 3.40% CAGR over the forecast period to reach US $251.84 million by 2027. 18 MM segment represented US $14.55 million opportunity over 2019-2021 and estimated to create US $50.83 million opportunity in 2027 over 2021.

20 MM

20 MM segment was valued at US $134.68 million in 2019 and is projected to grow at 3.40% CAGR over the forecast period to reach US $181.91 million by 2027. 20 MM segment represented US $10.51 million opportunity over 2019-2021 and estimated to create US $36.71 million opportunity in 2027 over 2021.

14 MM

14 MM segment was valued at US $51.63 million in 2019 and is projected to grow at 3.40% CAGR over the forecast period to reach US $69.73 million by 2027. 14 MM segment represented US $4.03 million opportunity over 2019-2021 and estimated to create US $14.07 million opportunity in 2027 over 2021.

OTHERS

OTHERS segment was valued at US $6.70 million in 2019 and is projected to grow at 3.40% CAGR over the forecast period to reach US $9.05 million by 2027. OTHERS segment represented US $0.52 million opportunity over 2019-2021 and estimated to create US $1.83 million opportunity in 2027 over 2021.

Region

Introduction

In 2021, NORTH AMERICA segment has the highest revenue of US $155.88 million and is expected to grow at CAGR of 3.40% by 2027 NORTH AMERICA segment has highest cagr growth of 3.40%.

NORTH AMERICA

NORTH AMERICA segment was valued at US $144.60 million in 2019 and is projected to grow at 3.40% CAGR over the forecast period to reach US $195.30 million by 2027. NORTH AMERICA segment represented US $11.28 million opportunity over 2019-2021 and estimated to create US $39.41 million opportunity in 2027 over 2021.

EUROPE

EUROPE segment was valued at US $108.08 million in 2019 and is projected to grow at 3.40% CAGR over the forecast period to reach US $145.97 million by 2027. EUROPE segment represented US $8.43 million opportunity over 2019-2021 and estimated to create US $29.46 million opportunity in 2027 over 2021.

ASIA-PACIFIC

ASIA-PACIFIC segment was valued at US $87.78 million in 2019 and is projected to grow at 3.40% CAGR over the forecast period to reach US $118.55 million by 2027. ASIA-PACIFIC segment represented US $6.85 million opportunity over 2019-2021 and estimated to create US $23.93 million opportunity in 2027 over 2021.

LAMEA

LAMEA segment was valued at US $39.02 million in 2019 and is projected to grow at 3.40% CAGR over the forecast period to reach US $52.70 million by 2027. LAMEA segment represented US $3.04 million opportunity over 2019-2021 and estimated to create US $10.64 million opportunity in 2027 over 2021.